Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis

Infection and Immunity

Volumn 82, Issue 8, 2014, Pages 3206-3213

  Scott, Andrew E ^a   Burtnick, Mary N ^b   Stokes, Margaret G M ^a   Whelan, Adam O ^a   Williamson, E Diane ^a   Atkins, Timothy P ^a   Prior, Joann L ^a   Brett, Paul J ^b  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; CAPSULAR POLYSACCHARIDE2B1 VACCINE; CARRIER PROTEIN; GLYCOCONJUGATE; HEPTOSE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOLC PROTEIN; O POLYSACCHARIDE2B1 VACCINE; POLYSACCHARIDE VACCINE; RECOMBINANT PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL VIRULENCE; BURKHOLDERIA PSEUDOMALLEI; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; LETHAL DOSE; MELIOIDOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL CAPSULES; BACTERIAL VACCINES; BURKHOLDERIA PSEUDOMALLEI; FEMALE; IMMUNOGLOBULIN G; MELIOIDOSIS; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; VACCINES, CONJUGATE;

EID: 84904758146     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01847-14     Document Type: Article

References (45)

1. Cheng AC, Currie BJ. 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18:383-416. http://dx.doi.org/10.1128/CMR.18.2.383-416.2005.
2. Currie BJ, Dance DAB, Cheng AC. 2008. The global distribution of Burkholderia pseudomallei and melioidosis: an update. Trans. R. Soc. Trop. Med. Hyg. 102:S1-S4. http://dx.doi.org/10.1016/S0035-9203(08)70002-6.
3. Wiersinga WJ, Currie BJ, Peacock SJ. 2012. Melioidosis. N. Engl. J. Med. 367:1035-1044. http://dx.doi.org/10.1056/NEJMra1204699.
4. Dance DAB. 2000. Ecology of Burkholderia pseudomallei and the interactions between environmental Burkholderia spp. and human-animal hosts. Acta Trop. 74:159-168. http://dx.doi.org/10.1016/S0001-706X(99)00066-2.
5. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. 2006. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat. Rev. Microbiol. 4:272-282. http://dx.doi.org/10.1038/nrmicro1385.
6. Meumann EM, Cheng AC, Ward L, Currie BJ. 2012. Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. Clin. Infect. Dis. 54:362-369. http://dx.doi.org/10.1093/cid/cir808.
7. Currie BJ, Ward L, Cheng AC. 2010. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20year Darwin prospective study. PLoS Negl. Trop. Dis. 4:e900. http://dx.doi.org/10.1371/journal.pntd.0000900.
8. Chaowagul W, White NJ, Dance DAB, Wattanagoon Y, Naigowit P, Davis TME, Looareesuwan S, Pitakwatchara N. 1989. Melioidosis: a major cause of community-acquired septicemia in Northeastern Thailand. J. Infect. Dis. 159:890-899. http://dx.doi.org/10.1093/infdis/159.5.890.
9. Currie BJ, Fisher DA, Howard DM, Burrow JNC, Lo D, Selva-nayagam S, Anstey NM, Huffam SE, Snelling PL, Marks PJ, Stephens DP, Lum GD, Jacups SP, Krause VL. 2000. Endemic melioidosis in tropical Northern Australia: a 10-year prospective study and review of the literature. Clin. Infect. Dis. 31:981-986. http://dx.doi.org/10.1086/318116.
10. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, Chetchotisakd P, Chaowagul W, Day NPJ, Peacock SJ. 2010. Increasing incidence of human melioidosis in Northeast Thailand. Am. J. Trop. Med. Hyg. 82:1113-1117. http://dx.doi.org/10.4269/ajtmh.2010.10-0038.
11. Silva EB, Dow SW. 2013. Development of Burkholderia mallei and pseudomallei vaccines. Front. Cell. Infect. Microbiol. 3:10. http://dx.doi.org/10.3389/fcimb.2013.00010.
12. Patel N, Conejero L, De Reynal M, Easton A, Bancroft GJ, Titball RW. 2011. Development of vaccines against Burkholderia pseudomallei. Front. Microbiol. 2:198. http://dx.doi.org/10.3389/fmicb.2011.00198.
13. Choh L C, Ong G H, Vellasamy KM, Kalaiselvam K, Kang W T, Al-Maleki AR, Mariappan V, Vadivelu J. 2013. Burkholderia vaccines: are we moving forward? Front. Cell. Infect. Microbiol. 3:5. http://dx.doi.org/10.3389/fcimb.2013.00005.
14. Galyov EE, Brett PJ, DeShazer D. 2010. Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis. Annu. Rev. Microbiol. 64:495-517. http://dx.doi.org/10.1146/annurev.micro.112408.134030.
15. Atkins T, Prior R, Mack K, Russell P, Nelson M, Prior J, Ellis J, Oyston P, Dougan G, Titball R. 2002. Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J. Med. Microbiol. 51:539-553. http://jmm.sgmjournals.org/content/51/7/539.long.
16. Reckseidler SL, DeShazer D, Sokol PA, Woods DE. 2001. Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect. Immun. 69:34-44. http://dx.doi.org/10.1128/IAI.69.1.34-44.2001.
17. DeShazer D, Brett PJ, Woods DE. 1998. The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol. Microbiol. 30:1081-1100.
18. Nelson M, Prior JL, Lever MS, Jones HE, Atkins TP, Titball RW. 2004. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J. Med. Microbiol. 53:1177- 1182. http://dx.doi.org/10.1099/jmm.0.45766-0.
19. Burtnick MN, Heiss C, Roberts RA, Schweizer HP, Azadi P, Brett PJ. 2012. Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders. Front. Cell. Infect. Microbiol. 2:108. http://dx.doi.org/10.3389/fcimb.2012.00108.
20. Brett PJ, Woods DE. 1996. Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect. Immun. 64:2824-2828.
21. Anuntagool N, Wuthiekanun V, White NJ, Currie BJ, Sermswan RW, Wongratanacheewin S, Taweechaisupapong S, Chaiyaroj SC, Sirisinha S. 2006. Lipopolysaccharide heterogeneity among Burkholderia pseudomallei from different geographic and clinical origins. Am. J. Trop. Med. Hyg. 74:348-352. http://www.ajtmh.org/content/74/3/348.long.
22. Zou N, Tsai S, Feng S H, Newsome T, Kim H Y, Li B, Zhang S, Lo S C. 2008. Relationship between antigenicity and pathogenicity for Burkholderia pseudomallei and Burkholderia mallei revealed by a large panel of mouse MAbs. Hybridoma 27:231-240. http://dx.doi.org/10.1089/hyb.2008.0012.
23. Jones S, Ellis J, Russell P, Griffin K, Oyston P. 2002. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J. Med. Microbiol. 51:1055-1062. http://jmm.sgmjournals.org/content/51/12/1055.long.
24. Bryan LE, Wong S, Woods DE, Dance DA, Chaowagul W. 1994. Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei. Can. J. Infect. Dis. 5:170-178.
25. Zhang S, Feng S H, Li B, Kim Y, Rodriguez J, Tsai S, Lo S C. 2011. In vitro and in vivo studies of monoclonal antibodies with prominent bactericidal activity against Burkholderia pseudomallei and Burkholderia mallei. Clin. Vaccine Immunol. 18:825-834. http://dx.doi.org/10.1128/CVI.00533-10.
26. AuCoin DP, Reed DE, Marlenee NL, Bowen RA, Thorkildson P, Judy BM, Torres AG, Kozel TR. 2012. Polysaccharide specific monoclonal antibodies provide passive protection against intranasal challenge with Burkholderia pseudomallei. PLoS One 7:e35386. http://dx.doi.org/10.1371/journal.pone.0035386.
27. Mond JJ, Lees A, Snapper CM. 1995. T cell-independent antigens type 2. Annu. Rev. Immunol. 13:655-692. http://dx.doi.org/10.1146/annurev.iy.13.040195.003255.
28. Snapper CM, Mond JJ. 1996. A model for induction of T cellindependent humoral immunity in response to polysaccharide antigens. J. Immunol. 157:2229-2233.
29. Weintraub A. 2003. Immunology of bacterial polysaccharide antigens. Carbohydr. Res. 338:2539-2547. http://dx.doi.org/10.1016/j.carres.2003.07.008.
30. Stein KE. 1992. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. 165:S49 -S52. http://dx.doi.org/10.1093/infdis/165-Supplement_1-S49.
31. Lockhart S. 2003. Conjugate vaccines. Expert Rev. Vaccines 2:633-648. http://dx.doi.org/10.1586/14760584.2.5.633.
32. Rappuoli R, Bagnoli F. 2011. Vaccine design. Caister Academic Press, Norfolk, United Kingdom.
33. Kelly DF, Snape MD, Clutterbuck EA, Green S, Snowden C, Diggle L, Yu L M, Borkowski A, Moxon ER, Pollard AJ. 2006. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood 108:2642-2647. http://dx.doi.org/10.1182/blood-2006-01 -009282.
34. Holden MTG, Titball RW, Peacock SJ, Cerdeño-Tárraga AM, Atkins T, Crossman LC, Pitt T, Churcher C, Mungall K, Bentley SD, Sebaihia M, Thomson NR, Bason N, Beacham IR, Brooks K, Brown KA, Brown NF, Challis GL, Cherevach I, Chillingworth T, Cronin A, Crossett B, Davis P, DeShazer D, Feltwell T, Fraser A, Hance Z, Hauser H, Holroyd S, Jagels K, Keith KE, Maddison M, Moule S, Price C, Quail MA, Rabbinowitsch E, Rutherford K, Sanders M, Simmonds M, Songsivilai S, Stevens K, Tumapa S, Vesaratchavest M, Whitehead S, Yeats C, Barrell BG, Oyston PCF, Parkhill J. 2004. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc. Natl. Acad. Sci. U. S. A. 101:14240-14245. http://dx.doi.org/10.1073/pnas.0403302101.
35. Heiss C, Burtnick MN, Roberts RA, Black I, Azadi P, Brett PJ. 2013. Revised structures for the predominant O-polysaccharides expressed by Burkholderia pseudomallei and Burkholderia mallei. Carbohydr. Res. 381: 6-11. http://dx.doi.org/10.1016/j.carres.2013.08.013.
36. Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS. 2007. Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect. Immun. 75:4173-4180. http://dx.doi.org/10.1128/IAI.00404-07.
37. Propst KL, Mima T, Choi KH, Dow SW, Schweizer HP. 2010. A Burkholderia pseudomallei delta purM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists. Infect. Immun. 78:3136-3143. http://dx.doi.org/10.1128/IAI.01313-09.
38. Perry MB, MacLean LL, Schollaardt T, Bryan LE, Ho M. 1995. Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect. Immun. 63:3348-3352.
39. Burtnick MN, Heiss C, Schuler AM, Azadi P, Brett PJ. 2012. Development of novel O-polysaccharide based glycoconjugates for immunization against glanders. Front. Cell. Infect. Microbiol. 2:148. http://dx.doi.org/10.3389/fcimb.2012.00148.
40. Scott AE, Laws TR, D'Elia RV, Stokes MGM, Nandi T, Williamson ED, Tan P, Prior JL, Atkins TP. 2013. Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing manno-heptose capsule. Clin. Vaccine Immunol. 20:1041-1047. http://dx.doi.org/10.1128/CVI.00113-13.
41. Chu KK, Tippayawat P, Walker NJ, Harding SV, Atkins HS, Maillere B, Bancroft GJ, Lertmemongkolchai G, Altmann DM. 2011. CD4 T-cell immunity to the Burkholderia pseudomallei ABC transporter LolC in melioidosis. Eur. J. Immunol. 41:107-115. http://dx.doi.org/10.1002/eji.201040881.
42. Tippayawat P, Saenwongsa W, Mahawantung J, Suwannasaen D, Chetchotisakd P, Limmathurotsakul D, Peacock SJ, Felgner PL, Atkins HS, Titball RW, Bancroft GJ, Lertmemongkolchai G. 2009. Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei. PLoS Negl. Trop. Dis. 3:e407. http://dx.doi.org/10.1371/journal.pntd.0000407.
43. Ngugi SA, Ventura VV, Qazi O, Harding SV, Kitto GB, Estes DM, Dell A, Titball RW, Atkins TP, Brown KA, Hitchen PG, Prior JL. 2010. Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis. Vaccine 28:7551-7555. http://dx.doi.org/10.1016/j.vaccine.2010.08.058.
44. Silva EB, Goodyear A, Sutherland MD, Podnecky NL, Gonzalez-Juarrero M, Schweizer HP, Dow SW. 2013. Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine. Infect. Immun. 81:4626-4634. http://dx.doi.org/10.1128/IAI.00915-13.
45. Healey GD, Elvin SJ, Morton M, Williamson ED. 2005. Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection. Infect. Immun. 73:5945-5951. http://dx.doi.org/10.1128/IAI.73.9.5945-5951.2005.